Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Nuclear RNAi Modulates Influenza A Virus Infectivity By Downregulating Type-I Interferon Response

ABSTRACT: Nuclear RNAi Modulates Influenza A Virus Infectivity By Downregulating Type-I Interferon Response

PROVIDER: PRJNA1129473 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR29639632.fastq.gz	Fastqsanger.gz
	SRR29639633.fastq.gz	Fastqsanger.gz
	SRR29639634.fastq.gz	Fastqsanger.gz
	SRR29639635.fastq.gz	Fastqsanger.gz
	SRR29639636.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 16

Similar Datasets

Nuclear RNAi Modulates Influenza A Virus Infectivity By Downregulating Type-I Interferon Response

Project description:The role of Argonaute (AGO) proteins and the RNA interference (RNAi) machinery in mammalian antiviral response has been debated. Therefore, we set out to investigate how mammalian RNAi impacts influenza A virus (IAV) infection. We demonstrate that IAV infection triggers nuclear accumulation of AGO2, which is directly facilitated by p53 activation. Mechanistically, we show that IAV induces nuclear AGO2 targeting of TRIM71, a proposed AGO2 E3 ligase, and type-I interferon-pathway genes for silencing. Hence, the RNAi machinery is highjacked by the virus to evade the immune system and support viral replication. We demonstrate that the FDA approved drug arsenic trioxide prevents nuclear AGO2:p53 accumulation, thereby increasing interferon response and decreasing viral replication in vitro and in a mouse model in vivo. Our data indicates that targeting the AGO2:p53-mediated silencing of innate immunity may offer a promising strategy to mitigate viral infections.

2025-03-13 | GSE271042 | GEO

Nuclear AGO2 Supports Influenza A Virus Infectivity By Downregulating Type-I Interferon Response

Project description:Nuclear AGO2 Supports Influenza A Virus Infectivity By Downregulating Type-I Interferon Response

| PRJNA1044762 | ENA

Nuclear AGO2 Supports Influenza A Virus Infectivity By Downregulating Type-I Interferon Response

Project description:Nuclear AGO2 Supports Influenza A Virus Infectivity By Downregulating Type-I Interferon Response

| PRJNA1044764 | ENA

Nuclear AGO2 Supports Influenza A Virus Infectivity By Downregulating Type-I Interferon Response

2025-03-23 | GSE248547 | GEO

Nuclear AGO2 Supports Influenza A Virus Infectivity By Downregulating Type-I Interferon Response

2025-03-23 | GSE248546 | GEO

Influenza virus facilitates its infectivity by activating p53 to inhibit the expression of interferon-induced transmembrane proteins (IFITMs)

Project description:Transcriptome analysis of mock or H1N1 IAV PR8 infected p53WT A549 and p53null A549-KO3 cells by Affymetrix GeneChip Human Transcriptome 2.0 Arrays to achieve a set of genes those are regulated by p53 and responsive to IAV infection. Influenza A virus infection activates cellular p53, however it has not been clear whether this process has pro- or anti- viral effects. In this study, using human isogenic p53 wildtype A549 cells and p53null A549-KO3 cells generated from the CRISPR/Cas9 technology, we report that p53null cells exhibit significantly reduced viral propagation property when infected with influenza A virus (H1N1/A/Puerto Rico/8/34). Here, using genome-wide microarray analysis we revealed that p53 regulates the expression of a large set of interferon-inducible genes, some of which are directly associated with viral infectivity and later experimentally validated to be responsible for p53-regulated IAV infectivity.

2018-05-31 | GSE106279 | GEO

Influenza virus facilitates its infectivity by activating p53 to inhibit the expression of interferon-induced transmembrane proteins (IFITMs)

Project description:Influenza virus facilitates its infectivity by activating p53 to inhibit the expression of interferon-induced transmembrane proteins (IFITMs)

| PRJNA416117 | ENA

A tick C1q protein alters infectivity of the Lyme disease agent by modulating interferon γ

Project description:A tick C1q protein alters infectivity of the Lyme disease agent by modulating interferon γ

| PRJNA854660 | ENA

Coronavirus and influenza virus triggers antiviral RNAi immunity [AIVKO_miRNA-seq]

Project description:RNA interference (RNAi) is a key antiviral immune mechanism in eukaryotes. However, in vertebrates such as birds and mammals, antiviral RNAi has only been observed in cells with poor interferon systems (stem cells and oocytes) or in viral suppressors of RNAi (VSR) deficiency virus infections. Our research originally discovered that infecting macrophages with wild-type coronavirus (Infectious bronchitis virus, IBV) and influenza viruses (Avian influenza virus, AIV) can trigger RNAi antiviral immunity and produce a certain amount of virus-derived siRNA (vsiRNA). These vsiRNAs have an inhibitory effect on the virus and carry out targeted silencing along the Dicer-Ago2-vsiRNA axis. Notably, these vsiRNAs are distributed throughout of the virus’s entire genome, with a predilection for A/U at the 5’ and 3’ termini of vsiRNA. In addition, Dicer cleavage produces vsiRNA based on the RWM motif, where R represents A/G, W represents A/C, and M represents A/U. Additionally, we discovered that avian LGP2 and MDA5 proteins positively impact the expression of the Dicer protein and the Dicer subtype “DicerM”, which exhibits a potent antiviral activity compared to Dicer itself. Most importantly, the psilencer4.1-plasmid constructed based on vsiRNA combined with nanomaterial polyetherimide (PEI) showed excellent anti-virus activity in specific-pathogen-free (SPF) chickens. These findings show that RNA viruses trigger the production of the vsiRNA in avian somatic cells, which is of great significance for the application of therapeutic vaccines in poultry.

2025-02-26 | GSE285056 | GEO

Coronavirus and influenza virus triggers antiviral RNAi immunity [IBV_miRNA-seq]

2025-02-26 | GSE285054 | GEO